Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erenumab - Amgen/Novartis

Drug Profile

Erenumab - Amgen/Novartis

Alternative Names: Aimovig; AMG-334; Erenumab-aooe

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Indiana University; Novartis; Rigshospitalet
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Headache; Rosacea; Temporomandibular joint dysfunction syndrome; Trigeminal neuralgia
  • Discontinued Hot flashes

Most Recent Events

  • 28 Feb 2023 Amgen has patent protection for erenumab in USA
  • 03 Jan 2023 Amgen terminates the phase II TMD CARE trial for Temporomandibular joint dysfunction syndrome in USA (SC) due to low enrolment rate (NCT05162027)
  • 27 Oct 2022 Amgen terminates phase-II trials in Trigeminal neuralgia in USA (SC) due to low enrollment rate (NCT05142228)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top